The effects of berberine on hyperhomocysteinemia and hyperlipidemia in rats fed with a long-term high-fat diet

Lipids in Health and Disease

Volumn 11, Issue , 2012, Pages

  Chang, Xin Xia ^a   Yan, Hong Mei ^a   Xu, Qiong ^a   Xia, Ming Feng ^a   Bian, Hua ^a   Zhu, Teng Fang ^a   Gao, Xin ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Berberine; Hyperhomocysteinemia; Hyperlipidemia

Indexed keywords

3 HYDROXY 3 METHYL GLUTARYL COENZYME A REDUCTASE; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOLIPOPROTEIN E; BERBERINE; CHOLESTEROL; EOSIN; HEMATOXYLIN; HOMOCYSTEINE; LIQUID NITROGEN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MESSENGER RNA; OXIDOREDUCTASE; UNCLASSIFIED DRUG;

AMINO ACID BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ATHEROSCLEROSIS; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIET RESTRICTION; DISSECTION; DOWN REGULATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HISTOPATHOLOGY; HYPERHOMOCYSTEINEMIA; HYPERLIPIDEMIA; LIPID DIET; LIPID LIVER LEVEL; LIVER; MALE; NONHUMAN; RAT; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT DURATION;

ANIMALS; AORTA; APOLIPOPROTEINS; ATHEROSCLEROSIS; BERBERINE; CHOLESTEROL; CHOLESTEROL, LDL; DIET, HIGH-FAT; DRUG EVALUATION, PRECLINICAL; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COA REDUCTASES; HYPERHOMOCYSTEINEMIA; HYPERLIPIDEMIAS; HYPOLIPIDEMIC AGENTS; LIPIDS; LIVER; MALE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, LIPOPROTEIN; RISK FACTORS;

RATTUS;

EID: 84863187406     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/1476-511X-11-86     Document Type: Article

References (32)

1. Hyperhomocysteinemia and arteriosclerosis: historical perspectives. McCully KS, Clin Chem Lab Med 2005 43 980 986 16197285 (Pubitemid 41581948)
2. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. Graham IM, Daly LE, Refsum HM, Robinson K, Brattstrom LE, Ueland PM, et al. JAMA 1997 277 1775 1781 10.1001/jama.1997.03540460039030 9178790 (Pubitemid 27247163)
3. Homocysteine and vascular disease. McCully KS, Nat Med 1996 2 386 389 10.1038/nm0496-386 8597939 (Pubitemid 26191904)
4. Homocysteine as a novel risk factor for atherosclerosis. Guthikonda S, Haynes WG, Curr Opin Cardiol 1999 14 283 291 10.1097/00001573-199907000-00002 10448607 (Pubitemid 29348717)
5. Studies on the hypoglycemic effect of Coptis chinensis and berberine. Chen QM, Xie MZ, Yao Xue Xue Bao 1986 21 401 406 3811923
6. Berberine improves lipid dysregulation in obesity by controlling central and peripheral AMPK activity. Kim WS, Lee YS, Cha SH, Jeong HW, Choe SS, Lee MR, et al. Am J Physiol 2009 296 812 E819
7. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Kong W, Wei J, Abidi P, Lin M, Inaba S, Li C, et al. Nature medicine 2004 10 1344 1351 10.1038/nm1135 15531889 (Pubitemid 40022716)
8. Berberine improves glucose metabolism through induction of glycolysis. Yin J, Gao ZG, Liu D, Liu ZJ, Ye JP, Am J Physiol Endocrinol Metab 2008 294 148 E156 17971514
9. Berberine reduces insulin resistance through protein kinase C-dependent up-regulation of insulin receptor expression. Kong WJ, Zhang H, Song DQ, Xue R, Zhao W, Wei J, et al. Metab Clin Exp 2009 58 109 119 10.1016/j.metabol.2008.08. 013 19059538
10. Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Lee YS, Kim WS, Kim KH, Yoon MJ, Cho HJ, Shen Y, et al. Diabetes 2006 55 2256 2264 10.2337/db06-0006 16873688 (Pubitemid 44743622)
11. Berberine reduces methylation of the MTTP promoter and alleviates fatty liver induced by a high-fat diet in rats. Chang X, Yan H, Fei J, Jiang M, Zhu H, Lu D, et al. Jounal of Lipid Research 2010 51 2504 2515 10.1194/jlr.M001958
12. Berberine promotes the development of atherosclerosis and foam cell formation by inducing scavenger receptor A expression in macrophage. Li K, Yao WQ, Zheng XD, Liao K, Cell Research 2009 19 1006 1017 10.1038/cr.2009.76 19546885
13. Spontaneous Hypercholesterolemia and Arterial Lesions in Mice Lacking Apolipoprotein-E. Zhang SH, Reddick RL, Piedrahita JA, Maeda N, Science 1992 258 468 471 10.1126/science.1411543 1411543
14. Severe Hypercholesterolemia and Atherosclerosis in Apolipoprotein-E- Deficient Mice Created by Homologous Recombination in Es Cells. Plump AS, Smith JD, Hayek T, Aaltosetala K, Walsh A, Verstuyft JG, et al. Cell 1992 71 343 353 10.1016/0092-8674(92)90362-G 1423598
15. Atherosclerosis in Mice Lacking Apo-E-Evaluation of Lesional Development and Progression. Reddick RL, Zhang SH, Maeda N, Arterioscler Thromb 1994 14 141 147 10.1161/01.ATV.14.1.141 8274470
16. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG, JAMA 1995 274 1049 1057 10.1001/jama.1995.03530130055028 7563456
17. A receptor-mediated pathway for cholesterol homeostasis. Brown MS, Goldstein JL, Science 1986 232 34 47 10.1126/science.3513311 3513311 (Pubitemid 16037973)
18. Cholesterol biosynthesis and metabolism. Russell DW, Cardiovasc Drugs Ther 1992 6 103 110 10.1007/BF00054556 1390320
19. Apoprotein E as a lipid transport and signaling protein in the blood, liver, and artery wall. Getz GS, Reardon CA, Journal of Lipid Research 2009 50 156 S161 19018038
20. Linton M, Atkinson J, Fazio S, Prevention of Atherosclerosis in Apolipoprotein E-Deficient Mice by Bone Marrow Transplantation Science. 1995 267 1034 1037
21. Nonalcoholic fatty liver disease. Adams LA, Angulo P, Lindor KD, CMAJ 2005 172 7 899 905 10.1503/cmaj.045232 15795412 (Pubitemid 40543601)
22. Effect of Apolipoprotein-B Synthesis Inhibition on Liver Triglyceride Content in Patients with Familial Hypercholesterolemia. Visser ME, Akdim F, Tribble DL, Nederveen AJ, Kwoh TJ, Kastelein JJP, et al. Journal of lipid research 2010 51 5 1057 1062 10.1194/jlr.M002915 20008831
23. Inhibition of microsomal triglyceride transfer protein: another mechanism of drug-induced steatosis in mice. Letteron P, Sutton A, Abdellah M, Fromenty B, Pessayre D, Hepatology 2003 38 133 140 12829995 (Pubitemid 36775804)
24. Stahelin HB [Hyperlipidemia and atherosclerosis in Switzerland. Results from the "Basler studie" (author's transl)]. Hartmann G, Ther Umsch 1980 37 980 984 7455963 (Pubitemid 11241143)
25. Experimental hyperlipidemia and atherosclerosis induced by cholesterol diet in SPF Japanese white rabbits. Nakayama S, Sakashita M, Tonooka M, Gotoh H, Yasuhara H, Sakamoto K, Jpn J Pharmacol 1983 33 279 289 10.1254/jjp.33.279 6887642 (Pubitemid 13079912)
26. Cigarette smoking, dietary hyperlipidemia, and experimental atherosclerosis in the baboon. Rogers WR, Carey KD, McMahan CA, Montiel MM, Mott GE, Wigodsky HS, et al. Exp Mol Pathol 1988 48 135 151 10.1016/0014-4800(88) 90051-2 3335249 (Pubitemid 18048526)
27. Hyperlipidemia in atherosclerosis. Dietary and drug treatment. Kuo PT, Med Clin North Am 1970 54 657 669 5429542
28. Homocysteine inhibits arterial endothelial cell growth through transcriptional downregulation of fibroblast growth factor-2 involving G protein and DNA methylation. Chang PY, Lu SC, Lee CM, Chen YJ, Dugan TA, Huang WH, et al. Circ Res 2008 102 933 941 10.1161/CIRCRESAHA.108.171082 18309099 (Pubitemid 351591555)
29. Increased monocyte adhesion to aortic endothelium in rats with hyperhomocysteinemia-Role of chemokine and adhesion molecules. Wang GP, Woo CWH, Sung FL, Siow YL OK, Arterioscler Thromb Vasc Biol 2002 22 1777 1783 10.1161/01.ATV.0000035404.18281.37 12426204 (Pubitemid 35331053)
30. Simvastatin exerts both anti-inflammatory and cardioprotective effects in apolipoprotein E-deficient mice. Scalia R, Gooszen ME, Jones SP, Hoffmeyer M, Rimmer DM, Trocha SD, et al. Circulation 2001 103 2598 2603 10.1161/01.CIR.103. 21.2598 11382730 (Pubitemid 32521971)
31. A simple method for the isolation and purification of total lipides from animal tissues. Folch J, Lees M, Sloane Stanley GH, J Biol Chem 1957 226 497 509 13428781
32. Hypermethylation of hepatic Gck promoter in ageing rats contributes to diabetogenic potential. Jiang MH, Fei J, Lan MS, Lu ZP, Liu M, Fan WW, et al. Diabetologia 2008 51 1525 1533 10.1007/s00125-008-1034-8 18496667